Oligonucleotide · developed by Sarepta Therapeutics
AVI-7537 is an agent given by intravenous infusion once daily for 14 days across several dose cohorts. It is studied in Ebola hemorrhagic fever.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01593072 | Phase 1 | Ebola Hemorrhagic Fever | Withdrawn | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ebola Hemorrhagic Fever
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →